HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.
以開發創新免疫生物藥物的全球臨床階段生技公司-漢康生技今天宣布，台灣衛生福利部食品藥物管理署 (TFDA) 已批准其在研新藥申請 (IND)，以開展獨立研發的新藥候選物 HCB101 的多區域臨床試驗，用於治療晚期實體瘤或復發難治性非霍奇金淋巴瘤患者。
1. 為何會創立漢康生技？
2. 漢康生技創立的時間跟宗旨是？
3. 目前為止，漢康生技已獲得哪些研發的成果或是募資上的成功？
4. 漢康生技的願景是甚麼?
5. 針對生物科技、醫療相關領域，漢康生技能為社會做些甚麼？
6. 漢康生技所研發的藥物跟其他傳統藥物的最大區別跟優勢是？關鍵技術是？
7. FBDB™是甚麼？特別之處是？它對研發上有哪些幫助？
8. 預計受惠者的規模或是程度為何？
9. 像這樣多種靶向模式的生物製劑，以重啟免疫系統來對抗疾病的機轉，是否能應用於其他疾病或醫學領域？
HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.
漢康生技（HanchorBio Inc.），一家專注於腫瘤免疫治療新藥研發與臨床的全球生技公司，今日宣佈其自主研發的創新融合蛋白HCB101獲得美國食品藥物管理局（FDA）授予新藥臨床試驗（IND）許可，即將開展多地區多中心的臨床試驗。此藥將用於治療晚期實體瘤及復發難治癒的非霍奇金淋巴瘤。
HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan with
world-renowned professors and few Board of Director (BOD) members.
漢康生技（HanchorBio Inc.）於2023年3月29日在台北內湖總部成功舉辦了(SAB)科學顧問委員會會議。
HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-medicines, completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023 in Taipei, Taiwan with world-renowned professors and few Board of Director (BOD) members.
Read More